Case Study #1: Applying a Clinical Genomic Nomogram to the ADT Decision in High Volume Gleason 3+4=7

Jeff M. Michalski, MD, MBA, FASTRO provides an overview of the novel decision making approach he’s developed as an extension of the clinical-genomic nomogram developed by Spratt et al. (JCO 2018). Dr. Michalski presents a case study of a man with high volume, Gleason 3+4=7 prostate cancer demonstrating how he uses the nomogram to help address the dilemma surrounding ADT-related decisions in newly-diagnosed intermediate risk prostate cancer patients.